Alto Neuroscience Inc. (NYSE: ANRO) has initiated a Phase 2b randomized, placebo-controlled trial of ALTO-207 for treatment-resistant depression, the company ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE